Brentuximab Vedotin with Chemotherapy in Adolescents and Young Adults (AYA) with Stage III or IV Hodgkin Lymphoma: A Subgroup Analysis from the Phase 3 Echelon-1 Study

Conclusions: This exploratory analysis of ECHELON-1 demonstrated that AYAs receiving A+AVD had significantly improved mPFS with a manageable tolerability profile compared with AYA patients receiving ABVD. A+AVD can be considered a treatment option for AYAs with advanced-stage cHL. Additional data presented will focus on comparing results between AYA age ranges.DisclosuresCrosswell: Seattle Genetics: Other: stock ownership in Seattle Genetics. LaCasce: Research to Practice: Speakers Bureau; Humanigen: Consultancy, Honoraria; Seattle Genetics: Consultancy, Honoraria; Bristol-Myers Squibb: Other: Data safety and monitoring board. Bartlett: Affimed: Research Funding; Pharmacyclics: Research Funding; Janssen: Research Funding; Bristol-Meyers Squibb: Research Funding; Merck & Co: Research Funding; KITE: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Celgene: Research Funding; Novartis: Research Funding; Immune Design: Research Funding; Genentech: Research Funding; Pharmacyclics: Research Funding; Gilead: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Pfizer: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Seattle Genetics: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Astra Zeneca: Research Funding; Novartis: Research Funding; Acerta: Membership on an entity's Board of ...

Source: Blood - November 21, 2018 Category: Hematology Authors: Crosswell, H. E., LaCasce, A. S., Bartlett, N. L., Straus, D. J., Savage, K. J., Fenton, K., Engley, G., Jolin, H., Liu, R., Zinzani, P. L., Collins, G. P., Grigg, A. P. Tags: 624. Hodgkin Lymphoma and T/NK Cell Lymphoma-Clinical Studies: Poster I Source Type: research